Efficacy/Safety Study to Confirm Iberogast’s Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo
Condition(s):Irritable Bowel SyndromeLast Updated:October 29, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Irritable Bowel SyndromeLast Updated:October 29, 2018Completed
Condition(s):Diarrhea Predominant Irritable Bowel SyndromeLast Updated:June 14, 2011Unknown status
Condition(s):Irritable Bowel Syndrome; Inflammatory Bowel DiseaseLast Updated:July 3, 2012Unknown status
Condition(s):Irritable Bowel SyndromeLast Updated:May 17, 2021Terminated
Condition(s):Irritable Bowel SyndromeLast Updated:March 31, 2016Completed
Condition(s):Irritable Bowel SyndromeLast Updated:June 5, 2012Completed
Condition(s):Irritable Bowel SyndromeLast Updated:September 29, 2022Completed
Condition(s):IBS – Irritable Bowel SyndromeLast Updated:December 14, 2022Completed
Condition(s):Irritable Bowel Syndrome; Quality of Life; Depression; Anxiety; StressLast Updated:January 30, 2024Completed
Condition(s):Irritable Bowel SyndromeLast Updated:July 6, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.